Nemunaitis John, Murray Nevin
Mary Crowley Medical Research Center, Dallas, Texas, USA.
J Thorac Oncol. 2006 Sep;1(7):756-61.
The limited efficacy and moderate toxicity of chemotherapy for non-small cell lung cancer (NSCLC) have given the search for a more effective and safer systemic treatment a sense of urgency. NSCLC has historically been regarded as a non-immunogenic cancer, and immunotherapy has yielded little benefit in humans. However, encouraging clinical results in patients immunized with novel vaccines directed toward enhancement of tumor antigen recognition have been published. In this review, we describe the scientific basis and updates the clinical results of three vaccine approaches (GVAX, Lucanix, and L-BLP25) and discuss preliminary work on a novel Ras mutation targeted immune therapy. Further studies are needed to demonstrate whether these novel therapies can potentially complement or replace current therapeutic approaches.
化疗对非小细胞肺癌（NSCLC）疗效有限且毒性中等，这使得寻找更有效、更安全的全身治疗方法变得刻不容缓。从历史上看，NSCLC一直被视为一种无免疫原性的癌症，免疫疗法在人体中收效甚微。然而，针对增强肿瘤抗原识别的新型疫苗免疫治疗患者的临床结果令人鼓舞，相关成果已发表。在本综述中，我们描述了三种疫苗疗法（GVAX、Lucanix和L-BLP25）的科学依据并更新了临床结果，还讨论了一种新型Ras突变靶向免疫疗法的初步研究工作。还需要进一步研究来证明这些新型疗法是否有可能补充或取代当前的治疗方法。
